QL2109 clinical trials
Also written QL2109.
How each study uses QL2109 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the QL2109 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- QL2109
- 3
Studies by the year they started
3 studies that test it; most in 2024 (1)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses QL2109 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male SubjectsNot yet recruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT07400744Written as QL2109
- A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy AdultsRecruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT06371534Written as QL2109
- To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple MyelomaNot yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT06742138Written as QL2109
Given beside what is tested · 2 — QL2109 is usual care or a partner of the new treatment
- Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple MyelomaRecruitingPhase 2Qilu Pharmaceutical Co., Ltd.NCT07018050Written as QL2109 or Daratumumab
- QLS4131 Combination Therapy in Malignant Plasma Cell NeoplasmsNot yet recruitingPhase 2Qilu Pharmaceutical Co., Ltd.NCT07560449Written as QL2109